Sun Pharma Stock - analyst consensus and strategy snapshot

Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 15:14 CET. Details in the imprint.

Sun Pharma (INE044A01036) remains one of India's largest generic and specialty drug makers by revenue and market value. With no fresh ad-hoc releases or major rating changes reported today, the midweek focus is on the company’s operational strategy and the prevailing analyst consensus.

What recent filings show

Sun Pharmaceutical Industries Ltd most recently reported its consolidated results for the financial year ended 03/31/2024, posting higher revenue and profit compared with the prior year, according to the company’s annual disclosures. IR documents on FY2024 performance

The group continues to emphasize specialty products, especially in dermatology and ophthalmology, alongside its established generic portfolio in India and export markets. Management has highlighted the US as a key growth driver, while also pointing to cost discipline and operational efficiencies.

Analyst consensus and ratings snapshot

Brokerage data compiled on financial portals indicate that the majority of covering analysts currently rate Sun Pharma stock at positive or neutral levels, typically clustered around "Buy" and "Hold" recommendations. Consensus overview on MarketScreener

Price targets published by large international and domestic houses span a range that implies limited to moderate upside from recent trading levels, reflecting both confidence in the franchise and caution about regulatory and competitive risks in key markets.

Operational priorities this Wednesday

With no new deal, regulatory notice or major site expansion announced today, investors are instead revisiting Sun Pharma’s medium-term priorities, such as expanding specialty revenues and maintaining compliance across its global manufacturing footprint.

The group operates formulation and active pharmaceutical ingredient plants in India and overseas, and has historically faced regulatory inspections from agencies such as the US Food and Drug Administration, making quality systems and remediation work a recurrent focus for the management team.

How the company makes money

Sun Pharma generates most of its revenue from selling generic and branded pharmaceutical formulations across India, the US and other international markets, complemented by active pharmaceutical ingredients supplied to other drug makers and internal use.

Where the stock trades today

The shares of Sun Pharmaceutical Industries Ltd (INE044A01036) trade on the National Stock Exchange of India at INR 1,600.00 as of 06/17/2026, 15:14 CET-equivalent market data.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.